Radical scavengers and the stability of 99mTc-radiopharmaceuticals

Fully automated preparation of 68Ga-PSMA-11 at curie level quantity using cyclotron-produced 68Ga for clinical applications

⁶⁸Ga-PSMA-11 is currently one of the most investigated PET agents for imaging both recurrent prostate cancer and relevant metastases; however, the production and distribution of ⁶⁸Ga-PSMA-11 is limited to a supply of only a few daily doses when using a commercially available ⁶⁸Ge/⁶⁸Ga generator. ⁶⁸Ge/⁶⁸Ga generators deliver only a modest amount of activity, up to 1850 MBq (50 mCi), when new, but it decreases with time. Additionally, the production of ⁶⁸Ga/⁶⁸Ge generators has not been able to meet the increasing demand of ⁶⁸Ga radiotracers. In response to the need for a more economically viable alternative, the focus of this study was to provide a simple and efficient method for producing ⁶⁸Ga-PSMA-11, using cyclotron-produced ⁶⁸Ga that is ready for routine clinical practice.

Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist

This study describes the discovery and development of an anaerobic formulation for the routine preparation of (90)Y and (177)Lu complexes ((90)Y-TA138 and (177)Lu-TA138) of a DOTA-conjugated nonpeptide vitronectin receptor antagonist (TA138: 3-sulfon-N-[[4,7,10-tris(carboxymethyl)1,4,7,10-tetraazacyclododec-1-yl]acetyl]-l-alanyl-N-[2-[4-[[[(1S)-1-carboxy-2[[[1,4-dihydro-7-[(1H-imidazol-2-ylamino]meth-yl]-1-methyl-4-oxo-3-quinolinyl]carbonyl]amino]ethyl]amino]-sulfonyl]-3,5-dimethylphenoxy]-1-oxobutyl]amino]ethyl]-3-sulfo-l-alaninamide). Since (90)Y-TA138 and (177)Lu-TA138 are very sensitive to radiolytic degradation, exclusion of oxygen is necessary during the radiolabeling. Using the anaerobic formulation, (90)Y-TA138 and (177)Lu-TA138 can be prepared in high yield and high specific activity. The anaerobic formulation described in this study is particularly useful for (90)Y- and (177)Lu-labeling of DOTA-conjugated small biomolecules, which are sensitive to the radiolytic degradation during radiolabeling.

Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals

The goal of this study is to explore the use of ascorbic acid (AA) as a buffer agent and a radiolytic stabilizer for preparation and stabilization of radiolabeled DOTA-biomolecule conjugates. Results from a titration experiment show that 0.1 M AA solution has sufficient buffer capacity at pH 5.0 while 0.5 M AA solution is useful even at pH 6.0. The radiolabeling experiment using TA138, a DOTA-conjugated nonpeptide integrin alpha(v)beta(3) receptor antagonist, clearly demonstrates that AA is a good buffer agent for pH control and an excellent antioxidant for stabilization of metal-labeled diagnostic ((111)In) and therapeutic ((90)Y and (177)Lu) radiopharmaceuticals if the radiolabeling is performed at pH 5-6. There is no need for the additional stabilizer (e.g., gentisic acid) and buffer agent such as ammonium acetate. The anaerobic AA formulation described in this study is particularly useful for radiolabeling of small biomolecules, which are sensitive to the radiolytic degradation during radiolabeling.

Alguns aspectos sobre geradores e radiofármacos de tecnécio-99m e seus controles de qualidade

Radiofármacos marcados com tecnécio-99m são os principais agentes para diagnósticos utilizados nas clínicas de medicina nuclear, em função de uma série de características físicas do radionuclídeo e pela praticidade dos radiofármacos serem preparados no local de uso, por meio de uma reação de complexação entre um agente complexante (fármaco) e o tecnécio-99m. Entretanto, durante esta reação podem ser geradas algumas impurezas que proporcionam a formação de produtos com baixa qualidade ou com características diferentes das desejadas. No presente trabalho serão apresentados alguns dos fatores que podem interferir na qualidade dos radiofármacos e os controles que podem ser utilizados para garantir sua qualidade.